HighField Files INDs for Two ADCplex™ Cancer Therapies
The new technology behind HighField’s immunoliposomes may offer greater safety and efficacy than existing antibody drug conjugates (ADCs) HighField Biopharmaceuticals, a clinical stage company using lipid-based...